drugset / Trial / NCT02489500
Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib
RandomizedParallel-groupOpen-labelTreatment
Summary
Standard treatment for AL Amyloidosis is high-dose melphalan and stem cell transplant. This study will compare the safety and effectiveness of standard treatment with high-dose melphalan and stem cell transplant, compared with investigational bortezomib when used in combination with standard treatment with high-dose melphalan and stem cell transplant for AL amyloidosis.
Timeline
- Start
- 2015-06
- Primary completion
- 2017-04-28
- Completion
- 2017-04-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1 mg/m2 | — |
| Background | Melphalan | Small molecule | 70 mg/m2 | — |
| Background | Melphalan | Small molecule | 100 mg/m2 | — |
| Background | filgrastim | Protein / enzyme biologic | 16 ug/kg | — |